Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9

Figure 3

Downregulation of Hsa-miR-105-1 promoted ANXA9 expression. A2780 and TOV-112D cells were transfected with scramble or the Hsa-miR-105-1 inhibitor. (a) The levels of ANXA9 mRNA expression as detected by the QPCR assay (, , and paired -test). (b) The levels of ANXA9 protein expression as detected by the western blotting. (c) The distribution of ANXA9 was shown by immunofluorescence. (d) The viability of scramble- or HAS-miR-105-1-treated A2780 or TOV-112D cells after exposure to different concentrations of cisplatin, as detected by the CCK8 assay. (e) The IC₅₀ values for A2780 and TOV-112D cells treated with the scramble or Hsa-miR-105-1 inhibitor when exposed to cisplatin (, , and paired -test).

(a)

(b)

(c)

(d)

(e)